# The C-reactive protein-to-body mass index ratio predicts prognosis in patients with different types of heart failure

## TL;DR

This study shows that a ratio of C-reactive protein to body mass index can predict mortality risk in heart failure patients, regardless of their heart function type.

## Contribution

The study introduces the C-reactive protein-to-body mass index ratio as a novel independent predictor of mortality in heart failure patients.

## Key findings

- High CBR group had the highest all-cause mortality in heart failure patients.
- CBR was an independent predictor of mortality across all types of heart failure.
- CBR showed better predictive accuracy than CRP or BMI alone.

## Abstract

The aim of this study was to explore the predictive value of the C-reactive protein-to-body mass index ratio (CBR) in the prognosis of all-cause mortality in patients with heart failure (HF) with different ejection fractions.

We included 1196 HF patients from the First Affiliated Hospital of Kunming Medical University after exclusion criteria. Based on the optimal cut-off value from the ROC curves, patients were categorised into low CBR group and high CBR group. The predictive value of the CBR for the prognosis of all-cause mortality in patients with different types of HF was assessed using Kaplan–Meier curves, Cox proportional hazards analyses, cubic spline plots and ROC curves analyses.

Kaplan‒Meier analyses showed that the high CBR group had the highest cumulative incidence of all-cause mortality regardless of the type of HF patients. Multivariate Cox regression analysis revealed that the CBR was an independent predictor of prognosis for all-cause mortality in patients with all types of HF. The cubic spline plots showed a roughly positive association between the CBR and all-cause mortality. The ROC curves showed that for all types of HF patients, the area under the curve for the CBR was the largest relative to individual CRP and BMI.

Regardless of the type of HF patients, the CBR can be a good predictor of prognosis for all-cause mortality in patients with a higher CBR associated with a higher risk of all-cause mortality.